How the pharmaceutical industry can turn the tide on mental health

RemedyOne provides the industry, clients and prospects years of collective experience from all healthcare disciplines, specifically a deep knowledge of health care systems that helps all associated with RemedyOne to grow and benefit from.
President

May is Mental Health Awareness Month. RemedyOne president Ralph Pisano wrote this article for Fierce Healthcare about how the pharmaceutical industry can do more to address the mental health crisis. 

The stigma of mental health disorders is slowly disappearing, and that’s a very good thing. You see evidence of this everywhere: on TV and social media, in ad reads on podcasts, even in the traditionally don’t-show-weakness world of professional sports. There is growing acceptance of discussions around mental health. 

Unfortunately, despite this cultural change, the prevalence of mental health disorders appears to be increasing, and well-known examples of its unfortunate consequences are all too common. 

Medication is a huge part of maintaining mental health for millions of Americans, but clearly the pharmaceutical industry is facing challenges in addressing this problem. I see three main obstacles to progress: adherence, cost and innovation.  

Read the full article on Fierce Healthcare. 

 

Facebook
Twitter
LinkedIn

Rebate and Formulary Management

RemedyOne cuts through the complexity of the pharmaceutical world by providing guidance and cost savings to PBMs, Employer Groups, Health Plans, and Third-Party Administrators.
Play Video

Rebate and Formulary Management

RemedyOne cuts through the complexity of the pharmaceutical world by providing guidance and cost savings to PBMs, Employer Groups, Health Plans, and Third-Party Administrators.
Play Video

Insights

Like what you’re seeing? Get more Insights sent to you.
  • This field is for validation purposes and should be left unchanged.